High Response Rates With Talquetamab in Advanced Myeloma High Response Rates With Talquetamab in Advanced Myeloma

The investigational, bispecific T-cell engager homes in on GPRC5D, a novel target unique to malignant plasma cells. It is awaiting approval from the Food and Drug Administration.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news